Actionable insights straight to your inbox

Equities logo

Trademark Application for “STEZORBAM” Filed by GlaxoSmithKline

By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for

By a News Reporter-Staff News Editor at Pharma Business Week — According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for “STEZORBAM” by Diane Fry Maginnis, representing GlaxoSmithKline. This application was made available to the public on June 27, 2014 (see also Trademarks).
The international trademark goods and services class code for this trademark application is 005.
The serial number for this application is 86182278.
As submitted by the applicant, this trademark application relates to the following goods and services: Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines.
The owner/registrar information for this application is: Diane Fry Maginnis, GlaxoSmithKline, 5 Moore Dr, Research Triangle Park, NC 27709-0183.
Keywords for this news article include: Pharmaceutical Companies, Trademarks, GlaxoSmithKline.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

A weekly five-point roundup of critical events in fintech, the future of finance and the next wave of banking industry transformation.